Canaan Partners X LLC
Insider CIK 1673228 · PTGX Director, 10% owner · ITRM Director, 10% owner · NXTC 10% owner · IDYA 10% owner · ASTR 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| ASTR Astra Space, Inc. | J Other | 2021-12-31 | 2022-01-04 | 4,200,000 | — | $0 | 16,489,668 | SEC↗ |
| ITRM Iterum Therapeutics plc | A Award deriv | 2020-01-21 | 2020-01-23 | 0 | $2000000.00 | $0 | 0 | SEC↗ |
| IDYA IDEAYA Biosciences, Inc. | C Conversion deriv | 2019-05-28 | 2019-05-28 | 602,549 | — | $0 | 0 | SEC↗ |
| IDYA IDEAYA Biosciences, Inc. | C Conversion deriv | 2019-05-28 | 2019-05-28 | 1,658,164 | — | $0 | 0 | SEC↗ |
| IDYA IDEAYA Biosciences, Inc. | P Buy | 2019-05-28 | 2019-05-28 | 400,000 | $10.00 | $4.00M | 2,660,713 | SEC↗ |
| IDYA IDEAYA Biosciences, Inc. | C Conversion | 2019-05-28 | 2019-05-28 | 1,658,164 | — | $0 | 1,658,164 | SEC↗ |
| IDYA IDEAYA Biosciences, Inc. | C Conversion | 2019-05-28 | 2019-05-28 | 602,549 | — | $0 | 2,260,713 | SEC↗ |
| NXTC NextCure, Inc. | C Conversion deriv | 2019-05-13 | 2019-05-13 | 3,582,000 | — | $0 | 0 | SEC↗ |
| NXTC NextCure, Inc. | C Conversion deriv | 2019-05-13 | 2019-05-13 | 2,296,605 | — | $0 | 0 | SEC↗ |
| NXTC NextCure, Inc. | C Conversion deriv | 2019-05-13 | 2019-05-13 | 5,861,455 | — | $0 | 0 | SEC↗ |
| NXTC NextCure, Inc. | C Conversion deriv | 2019-05-13 | 2019-05-13 | 5,970,000 | — | $0 | 0 | SEC↗ |
| NXTC NextCure, Inc. | C Conversion | 2019-05-13 | 2019-05-13 | 743,110 | — | $0 | 1,188,976 | SEC↗ |
| NXTC NextCure, Inc. | C Conversion | 2019-05-13 | 2019-05-13 | 285,867 | — | $0 | 2,204,442 | SEC↗ |
| NXTC NextCure, Inc. | C Conversion | 2019-05-13 | 2019-05-13 | 729,599 | — | $0 | 1,918,575 | SEC↗ |
| NXTC NextCure, Inc. | C Conversion | 2019-05-13 | 2019-05-13 | 445,866 | — | $0 | 445,866 | SEC↗ |
| NXTC NextCure, Inc. | P Buy | 2019-05-13 | 2019-05-13 | 50,000 | $15.00 | $750.0K | 2,254,442 | SEC↗ |
| ITRM Iterum Therapeutics plc | C Conversion deriv | 2018-05-30 | 2018-05-30 | 275,446 | — | $0 | 0 | SEC↗ |
| ITRM Iterum Therapeutics plc | C Conversion deriv | 2018-05-30 | 2018-05-30 | 229,660 | — | $0 | 0 | SEC↗ |
| ITRM Iterum Therapeutics plc | C Conversion deriv | 2018-05-30 | 2018-05-30 | 721,408 | — | $0 | 0 | SEC↗ |
| ITRM Iterum Therapeutics plc | C Conversion | 2018-05-30 | 2018-05-30 | 229,660 | — | $0 | 1,226,514 | SEC↗ |
| ITRM Iterum Therapeutics plc | C Conversion | 2018-05-30 | 2018-05-30 | 721,408 | — | $0 | 721,408 | SEC↗ |
| ITRM Iterum Therapeutics plc | P Buy | 2018-05-30 | 2018-05-30 | 506,656 | $13.00 | $6.59M | 1,733,170 | SEC↗ |
| ITRM Iterum Therapeutics plc | C Conversion | 2018-05-30 | 2018-05-30 | 275,446 | — | $0 | 996,854 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2018-05-17 | 2018-05-21 | 38,968 | $6.09 | $237.3K | 2,116,552 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2018-05-16 | 2018-05-16 | 29,441 | $6.46 | $190.2K | 2,155,520 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2018-05-15 | 2018-05-16 | 57,715 | $6.48 | $374.0K | 2,184,961 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2018-05-14 | 2018-05-16 | 77,591 | $6.37 | $494.3K | 2,242,676 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2018-03-23 | 2018-03-26 | 59,950 | $20.71 | $1.24M | 2,320,267 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2018-03-22 | 2018-03-22 | 4,759 | $20.62 | $98.1K | 2,380,217 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2018-03-21 | 2018-03-22 | 17,699 | $20.61 | $364.8K | 2,384,976 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2018-03-20 | 2018-03-22 | 17,060 | $20.61 | $351.6K | 2,402,675 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2018-03-19 | 2018-03-19 | 13,439 | $20.57 | $276.4K | 2,419,735 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2018-03-16 | 2018-03-19 | 6,926 | $20.51 | $142.1K | 2,433,174 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2018-03-15 | 2018-03-15 | 11,751 | $20.64 | $242.5K | 2,440,100 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2018-03-14 | 2018-03-15 | 200 | $20.77 | $4.2K | 2,451,851 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2018-03-13 | 2018-03-15 | 1,204 | $20.84 | $25.1K | 2,452,051 | SEC↗ |
| PTGX Protagonist Therapeutics, | C Conversion deriv | 2016-08-16 | 2016-08-16 | 27,113,877 | — | $0 | 0 | SEC↗ |
| PTGX Protagonist Therapeutics, | C Conversion | 2016-08-16 | 2016-08-16 | 1,869,922 | — | $0 | 1,869,922 | SEC↗ |
| PTGX Protagonist Therapeutics, | P Buy | 2016-08-16 | 2016-08-16 | 583,333 | $12.00 | $7.00M | 2,453,255 | SEC↗ |